Author

M. Kawamoto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Ohgitani· 2 shared H. Kinugasa· 2 shared M. Ichitani· 2 shared M. Kobayashi· 2 shared M. Shin-Ya· 2 shared O. Mazda· 2 shared T. Takihara· 2 shared A. Hoellein· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

E. Ohgitani

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Rapid inactivation in vitro of SARS-CoV-2 in saliva by black tea and green tea

E. Ohgitani, M. Shin-Ya, M. Ichitani, M. Kobayashi, T. Takihara, M. Kawamoto, H. Kinugasa, O. Mazda

This study shows that black and green tea can inactivate SARS-CoV-2 in saliva within 10 seconds, suggesting potential for reducing viral spread.

bioRxiv · Dec 28, 2020Microbiology

Significant inactivation of SARS-CoV-2 by a green tea catechin, a catechin-derivative and galloylated theaflavins in vitro

E. Ohgitani, M. Shin-Ya, M. Ichitani, M. Kobayashi, T. Takihara, M. Kawamoto, H. Kinugasa, O. Mazda

The paper investigates the in vitro antiviral effects of green tea and its derivatives against SARS-CoV-2, finding that certain compounds significantly reduce virus infectivity.

bioRxiv · Dec 4, 2020Microbiology

Complement- and inflammasome-mediated autoinflammation-paroxysmal nocturnal hemoglobinuria

B. Hoechsmann, Y. Murakami, M. Osato, A. Knaus, M. Kawamoto, N. Inoue, T. Hirata, S. Murata, M. Anliker, T. Eggerman, M. Jaeger, R. Floettmann, A. Hoellein, S. Murase, Y. Ueda, , T. Kinoshita

This study identifies AIF-PNH as a disease caused by germline and somatic mutations in PIGT, leading to complement activation and inflammasome-mediated IL-1β secretion, which is treatable with eculizumab.

bioRxiv · May 13, 2019 · PreprintImmunology